Product Details
Product Details
Product Specification
| Host | Rabbit |
| Antigen | IL-29, IL-28A, IL-28B |
| Synonyms | IL-29/IFN-λ1, IL-28A/IFN-λ2, IL-28B/IFN-λ3 |
| Immunogen | Recombinant Protein |
| Clone Number | SDT-1838-9 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG |
| Application | Sandwich ELISA |
| Reactivity | Hu |
| Cross Reactivity | Cross-reactivity with IL-28A, IL-28B, IL-29 |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, 0.03% Proclin 300 |
| Stability & Storage | 12 months from date of receipt, 2 to 8 °C as supplied |
Background
IL-28A, IL-28B, and IL-29, also named interferon-lambda 2 (IFN-lambda 2), IFN-lambda 3, and IFN-lambda 1, respectively, are newly identified class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13% a.a. sequence identity) and the type IIFN family (15-19 % a.a. sequence identity). The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and upregulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor lambda (IL-10 R beta) and a novel IL-28 receptor alpha (IL-28 R alpha, also known as IFN-lambda R1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation.
Picture
Picture
Paired Recommendations
